KalVista Pharmaceuticals, Inc. (KALV) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
KALV EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KALV Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export KALV earnings history in CSV or JSON format
Free sign-in required to download data
KalVista Pharmaceuticals, Inc. (KALV) Earnings Overview
As of May 8, 2026, KalVista Pharmaceuticals, Inc. (KALV) reported trailing twelve-month net income of -$210M, reflecting -7.3% year-over-year growth. The company earned $-3.90 per diluted share over the past four quarters.
Looking at the long-term picture, KALV's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
KalVista Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BDTX ($21M net income), PRAX (-$327M net income), KALA (-$36M net income), KALV has comparable earnings metrics. Compare KALV vs BDTX →
KALV Earnings vs Peers
Earnings metrics vs comparable public companies
KALV Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$183M | -44.9% | -$188M | $-3.69 | - | - |
| 2024 | -$127M | -36.3% | -$140M | $-3.44 | - | - |
| 2023 | -$93M | -12.8% | -$111M | $-3.33 | - | - |
| 2022 | -$82M | -78.1% | -$97M | $-3.36 | - | - |
| 2021 | -$46M | -58.8% | -$58M | $-2.33 | - | - |
| 2020 | -$29M | -39.9% | -$41M | $-1.64 | -229.4% | -319.4% |
| 2019 | -$21M | -31.7% | -$30M | $-1.38 | -129.1% | -184.9% |
| 2018 | -$16M | +15.0% | -$19M | $-1.53 | -188.3% | -222.8% |
| 2017 | -$19M | -62.7% | -$22M | $-1.92 | -1236.9% | -1485.3% |
| 2016 | -$11M | -58.3% | -$15M | $-2.40 | -536.1% | -711.7% |
See KALV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KALV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KALV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKALV — Frequently Asked Questions
Quick answers to the most common questions about buying KALV stock.
Is KALV growing earnings?
KALV EPS fell to $-3.90, with earnings declining -7.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-210M.
What are KALV's profit margins?
KalVista Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are KALV's earnings?
KALV earnings data spans 2013-2025. The declining earnings trend is -7.3% YoY. Historical data enables comparison across business cycles.